Marilyn  Kwan  to  Antineoplastic Agents, Hormonal
                            
                            
                                This is a "connection" page, showing publications  Marilyn  Kwan  has written about  Antineoplastic Agents, Hormonal.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            2.649
         
        
        
     
 
    
        
        - 
            Description of Major Osteoporotic Fractures in Women with Invasive Breast Cancer Who Received Endocrine Therapy. JAMA Netw Open. 2021 11 01; 4(11):e2133861.
            
            
                Score: 0.729
             
- 
            Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
            
            
                Score: 0.557
             
- 
            Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun; 28(6):557-562.
            
            
                Score: 0.530
             
- 
            Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
            
            
                Score: 0.484
             
- 
            Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020 Feb; 180(1):187-195.
            
            
                Score: 0.161
             
- 
            Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr; 126(2):529-37.
            
            
                Score: 0.084
             
- 
            Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug; 201(1):117-126.
            
            
                Score: 0.051
             
- 
            Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018 Aug; 170(3):623-631.
            
            
                Score: 0.036
             
- 
            Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2009 Nov; 118(2):395-405.
            
            
                Score: 0.019